Form 4 for CRL Charles River Laboratories
Accepted 2026-06-02 16:40:38 ET · period of report 2026-05-29 · accession 0001100682-26-000097 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 16:40 | 2026-05-29 | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | A - Grant | $180.71 | +5,257 | 32.3K | +19% | +$950.0K | |
| M | 2026-06-02 16:40 | 2026-05-30+ | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | F - Tax | $180.71 | -979 | 31.3K | -3% | -$176.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-29 | A | A | 5,257 | $180.71 | 32,277 | D | — | — | (F1) Unvested restricted stock units annually ratably vest on: May 29, 2027; May 29, 2028; May 29, 2029; May 29, 2030. |
| 2 | Common | Common Stock | 2026-05-30 | F | D | 744 | $180.71 | 31,533 | D | — | — | |
| 3 | Common | Common Stock | 2026-05-31 | F | D | 235 | $180.71 | 31,298 | D | — | — |